Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington s disease
Alchemab using unique approach to explore adaptive immunity identifying naturally protective antibodies in resilient patients to specific diseases
Innovate UK Grant to support the finding of a disease-modifying therapy for Huntington s disease (HD), a degenerative disease with no cure and no therapies to prevent progression
Alchemab is working in collaboration with Medicines Discovery Catapult, a not-for-profit, government-funded organisation supporting UK life science innovators
HD samples being supplied by CHDI Foundation
Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington s disease (HD). The grant
Investment Week is hosting its Global Emerging Markets Briefing at a pivotal time for investors as they start to position for the recovery from the Covid-19 pandemic, although risks remain.
During this interactive briefing, we will hear from a number of global emerging market managers about their response to the extraordinary events of the past year and their outlook for the rest of the year and beyond.
The managers will identify where they are seeing the biggest opportunities and risks at the moment in emerging markets and explain the role their strategies could play in client portfolios.
Attendees will also get the chance to network with peers, quiz our speakers, as well as benefit from CPD points
A busy year despite a COVID-19 pause
Share
Downtown Milwaukee
Southeastern Wisconsin companies continued to evolve through mergers and acquisitions over the past year. Here is a look at some of the region’s other significant deals: Wauwatosa-based insurance software company Zywave Inc. was acquired by…
Want to Read More?
Southeastern Wisconsin companies
continued to evolve through mergers and acquisitions over the past year. Here is a look at some of the region’s other significant deals:
Wauwatosa-based insurance software company
Zywave Inc. was acquired by California-based private equity firm Clearlake Capital Group, L.P. from Los Angeles-based Aurora Capital Partners. Members of the management team, including CEO Jason Liu, invested alongside Clearlake Capital. Zywave also continued making its own deals, acquiring Texas-based Insurance Technologies Corp. and New York-based Advisen, which helped expand its international presence.
Published: Feb 24, 2021
Feb. 24, 2021 11:00 UTC
Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors
Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic
Two investigational new drug (IND) applications planned in 2021
Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95 million Series C financing. Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials. Investigational new drug (IND) applications for XTX202 and XTX101 are expected to be filed with the U.S. Food and Drug Administration (FDA) in 2021.
New Mexico Educational assigns $105 million to alternatives
AE Industrial Partners Extended Value Fund, said Bob Jacksha, CIO of the $14.2 billion pension fund.
The private equity fund focuses on aerospace and related industries.
The board also made a total of $35 million in follow-on commitments to private equity funds in which the pension fund is already invested. The board committed an additional $15 million to SV Health Growth Fund VII, a specialist health-care fund managed by SV Health Investors. The board had previously committed $35 million to the fund.
Pension officials also committed another $10 million each to B Capital Opportunities Fund I, a venture capital fund managed by B Capital Group; and Tenex Capital Partners III, a private equity fund managed by Tenex Capital Management. The board s previous commitment to the B Capital fund was $30 million and to the Tenex fund, $50 million.